Development of a Blood-Based Biomarker Panel for Indeterminate Lung Nodules
Technical Report,01 Sep 2015,31 Aug 2016
University of Texas MD Anderson Cancer Center Houston United States
Pagination or Media Count:
Lung cancer screening with low-dose CT LDCT has been shown to reduce mortality by 20 , although there are concerns including high false positivity, cost, and radiation exposure. Blood-based markers are a promising and attractive approach to complement LDCT because of the potential to identify those subjects that need to undergo further work-up for their indeterminate nodules. The main objective of my proposed project is to develop a blood-based biomarker panel from three platforms protein, autoantibody and microRNA to distinguish malignant lung nodules from benign lung nodules. We have so far assayed 20 protein markers, 122 autoantibodies, 20 microRNAs, and a metabolite DAS, in the 149 malignant lung nodules and 187 benign lung nodules.
- Medicine and Medical Research